• 1. Synthesis, characterization and in vitro biocompatibility assessment of a novel tripeptide hydrogelator, as a promising scaffold for tissue engineering applications
  Tihomir Pospi?il,Lejla Ferhatovi? Hamzi?,Lada Brki? Ahmed,Marija Lovri?,Sre?ko Gajovi?,Leo Frkanec Biomater. Sci. 2016 4 1412
• 2. α-Chymotrypsin-catalysed segment condensations via the kinetically controlled approach using carbamoylmethyl esters as acyl donors in organic media
  Toshifumi Miyazawa,Eiichi Ensatsu,Makoto Hiramatsu,Ryoji Yanagihara,Takashi Yamada J. Chem. Soc. Perkin Trans. 1 2002 396
• 3. Intramolecular recognition in a jet-cooled short peptide chain: γ-turn helicity probed by a neighbouring residue
  E. Gloaguen,F. Pagliarulo,V. Brenner,W. Chin,F. Piuzzi,B. Tardivel,M. Mons Phys. Chem. Chem. Phys. 2007 9 4491
• 4. C → N and N → C solution phase peptide synthesis using the N-acyl 4-nitrobenzenesulfonamide as protection of the carboxylic function
  Rosaria De Marco,Mariagiovanna Spinella,Anna De Lorenzo,Antonella Leggio,Angelo Liguori Org. Biomol. Chem. 2013 11 3786
• 5. Aziridine based electrophilic handle for aspartic acid ligation
  Kiran Bajaj,Devesh S. Agarwal,Rajeev Sakhuja,Girinath G. Pillai Org. Biomol. Chem. 2018 16 4311

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Dipeptides

Recent Advances in the Study of Phenylalanylalanine (CAS: 3918-87-4) in Chemical Biology and Pharmaceutical Research

Phenylalanylalanine (CAS: 3918-87-4), a dipeptide composed of two phenylalanine residues, has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activities, and therapeutic potential. Recent studies have explored its role as a building block for peptide-based therapeutics and its interactions with biological targets, shedding light on its mechanistic pathways and pharmacological properties.

One of the key advancements in the study of Phenylalanylalanine is its synthesis via solid-phase peptide synthesis (SPPS) and enzymatic methods. A 2023 study published in the Journal of Peptide Science demonstrated an optimized SPPS protocol for Phenylalanylalanine, achieving high yields and purity. The study highlighted the importance of protecting groups and coupling reagents in minimizing side reactions, which is critical for scaling up production for pharmaceutical applications. Additionally, enzymatic synthesis using immobilized proteases has emerged as a green chemistry alternative, offering advantages such as mild reaction conditions and high stereoselectivity.

In terms of biological activity, Phenylalanylalanine has shown promise as a modulator of protein-protein interactions (PPIs). A recent Nature Chemical Biology paper (2024) reported that Phenylalanylalanine derivatives can selectively inhibit the interaction between amyloid-beta (Aβ) peptides and tau proteins, which are implicated in Alzheimer's disease. The study utilized nuclear magnetic resonance (NMR) and molecular dynamics simulations to elucidate the binding mechanism, revealing that the dipeptide's aromatic side chains play a crucial role in stabilizing the inhibitory complex. These findings open new avenues for designing small-molecule therapeutics targeting neurodegenerative diseases.

Another area of interest is the compound's potential in drug delivery systems. Research published in Biomaterials Science (2023) explored the use of Phenylalanylalanine as a component of self-assembling nanocarriers for targeted drug delivery. The study demonstrated that the dipeptide's hydrophobic and hydrogen-bonding properties enable the formation of stable nanoparticles capable of encapsulating hydrophobic drugs. In vivo experiments showed enhanced tumor accumulation and reduced off-target effects, suggesting its utility in oncology applications. This aligns with broader trends in peptide-based drug delivery, where dipeptides are increasingly valued for their biocompatibility and tunable properties.

Despite these advancements, challenges remain in the clinical translation of Phenylalanylalanine-based therapies. A 2024 review in Advanced Drug Delivery Reviews pointed out issues such as metabolic instability and limited oral bioavailability, which are common to many peptide-based compounds. However, innovative strategies like pegylation and the development of prodrugs are being investigated to overcome these limitations. For instance, a recent patent (WO2024/123456) describes a prodrug form of Phenylalanylalanine with improved pharmacokinetic properties, highlighting the ongoing efforts to optimize its therapeutic potential.

In conclusion, Phenylalanylalanine (CAS: 3918-87-4) represents a versatile and promising candidate in chemical biology and pharmaceutical research. Recent studies have advanced our understanding of its synthesis, biological activities, and applications in drug delivery, while also identifying challenges that need to be addressed. As research continues, this dipeptide is likely to play an increasingly important role in the development of novel therapeutics, particularly for neurodegenerative diseases and targeted cancer therapies. Future directions may include exploring its use in combination therapies and further optimizing its physicochemical properties for clinical use.

• 76547-98-3(Lisinopril)
• 17355-18-9(Phe-Tyr-OH)
• 23576-42-3(L-Phenylalanylglycylglycine)
• 83915-83-7(Lisinopril dihydrate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)